Drug reference
Prevention and treatment of ventricular and supraventricular arrhythmias, including after myocardial infarction | Maintenance of sinus rhythm after cardioversion ▶BY MOUTH USING IMMEDIATE-RELEASE MEDICINES ▶Adult: 300–800 mg daily in divided doses ▶BY MOUTH USING MODIFIED-RELEASE MEDICINES ▶Adult: 250–375 mg every 12 hours
PDF page 132
Bundle-branch block associated with first-degree AV block. pre-existing long QT syndrome . second- and third-degree AV block or bifascicular block (unless pacemaker fitted). severe heart failure (unless secondary to arrhythmia). severe sinus node dysfunction
PDF page 132
Atrial flutter or atrial tachycardia with partial block. avoid in Acute porphyrias p. 1120. elderly. heart failure (avoid if severe). myasthenia gravis. prostatic enlargement. structural heart disease. susceptibility to angle-closure glaucoma
PDF page 132
→Appendix 1: antiarrhythmics
PDF page 132
Abdominal pain. appetite decreased. arrhythmias. cardiac conduction disorders. cardiogenic shock. cognitive disorder. constipation. diarrhoea. dizziness. dry mouth. erectile dysfunction. headache. heart failure. hyperhidrosis. hypoglycaemia. hypotension . jaundice cholestatic. nausea. neutropenia. psychotic disorder. QT interval prolongation. rash. urinary disorders. vision disorders. vomiting
PDF page 132
Manufacturer advises use only if potential benefit outweighs risk; may induce labour if used in third trimester.
PDF page 132
Present in milk—use only if essential. Monitoring Monitor infant for antimuscarinic effects.
PDF page 132
For immediate-release capsules, manufacturer advises caution (risk of increased half-life). For modified-release tablets, manufacturer advises avoid. Dose adjustments For immediate-release capsules, manufacturer advises consider dose reduction.
PDF page 132
Avoid modified-release preparation. Dose adjustments Reduce dose by increasing dose interval; adjust according to response.
PDF page 132
▶Monitor for hypotension, hypoglycaemia, ventricular tachycardia, ventricular fibrillation or torsade de pointes (discontinue if occur). ▶Monitor serum potassium.
PDF page 132
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: capsule, oral suspension, oral solution Modified-release tablet CAUTIONARY AND ADVISORY LABELS 25 ▶Rythmodan Retard (Sanofi) Disopyramide (as Disopyramide phosphate) 250 mg Rythmodan Retard 250mg tablets | 60 tablet P £32.08 DT = £32.08 Capsule ▶Disopyramide (Non-proprietary) Disopyramide 100 mg Disopyramide 100mg capsules | 84 capsule P £26.51 DT = £26.51 Disopyramide 150 mg Disopyramide 150mg capsules | 84 capsule P £33.40 DT = £33.09 ▶Rythmodan (Sanofi) Disopyramide 100 mg Rythmodan 100mg capsules | 84 capsule P £14.14 DT = £26.51 ANTIARRHYTHMICS › CLASS IC
PDF page 132
300–800 mg daily in divided doses
First-line fragment. Read the complete Indications and Dose section above.
PDF page 132
250–375 mg every 12 hours
First-line fragment. Read the complete Indications and Dose section above.
PDF page 132
